IP Library › Granted Patent US 12,551,543
Granted Patent B2
US 12,551,543 · App. 17/691,468 · Granted Feb 17, 2026

Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof

Inventor: Mads Hald Andersen (Naerum, DK)
Assignee: IO Biotech ApS
A61K39/001142A61K38/195A61K39/0011A61K48/00A61P35/00C07K14/521C12N15/85C12N15/86A61K40/4236
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,551,543
App. No.
17/691,468
Granted
Feb 17, 2026
Kind
B2
Abstract

The present disclosure relates to CCL22 as a T cell target in cancer immunosuppression.

Claims (7)

1 . A method of treating a cancer where C—C Motif Chemokine 22 (CCL22) is expressed, the method comprising administering to an individual suffering from said cancer a composition comprising an immunogenically active peptide fragment of CCL22 consisting of at least 25 and not more than 50 consecutive residues of SEQ ID NO: 12,

wherein the peptide fragment comprises a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 11,

wherein the method inhibits recruitment of immune suppressive cells to a CCL22-expressing tumor, and

wherein CCL22-expressing cells are lysed by T cells reactive to the administered peptide.

2 . The method of claim 1 , wherein the method comprises administering a further cancer treatment, and wherein the further cancer treatment is chemotherapy or radiotherapy.

3 . The method according to claim 1 , wherein the composition further comprises an adjuvant.

4 . The method according to claim 3 , wherein the adjuvant is selected from the group consisting of bacterial DNA based adjuvants, oil/surfactant based adjuvants, viral dsRNA based adjuvants and imidazoquinolines.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2022
From: HERLEV HOSPITAL
To: IO BIOTECH APS
Reel/Frame 061415/0400 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2022
From: ANDERSEN, MADS HALD
To: HERLEV HOSPITAL
Reel/Frame 061354/0980 →
Priority Claims (1)
DK PA 2015 70591 · Sep 16, 2015 · national
Continuity (2)
Division 15758187
Related Publication 20220339273A1 · Oct 27, 2022
References Cited (31)
US 7018627B1 · Gray et al. · 2006 [cited by applicant]
US 8563476B2 · Lillard, Jr. · 2013 [cited by examiner]
US 10130454B2 · Jones et al. · 2018 [cited by applicant]
US 10329336B2 · Yount · 2019 [cited by examiner]
US 11298413B2 · Andersen · 2022 [cited by applicant]
US 11413245B2 · Little · 2022 [cited by examiner]
US 20060057112A1 · Gray et al. · 2006 [cited by applicant]
US 20070099844A1 · Prendergast · 2007 [cited by examiner]
US 20140363495A1 · Schlom et al. · 2014 [cited by applicant]
US 20220280624A1 · Andersen · 2022 [cited by applicant]
WO WO9640923A1 · 1996 [cited by applicant]
WO WO200078334A1 · 2000 [cited by applicant]
WO WO2009143843A1 · 2009 [cited by applicant]
WO WO2011139738A1 · 2011 [cited by applicant]
WO WO2013056716A1 · 2013 [cited by applicant]
WO WO2014028644A1 · 2014 [cited by applicant]
WO WO2014037811A2 · 2014 [cited by applicant]
WO WO2014170389A1 · 2014 [cited by applicant]
Harrington et al., Int'l. J. Psychiatry in Medicine, vol. 40(2) 163-181, 2010. [cited by examiner]
Cleeland, Seminars in Radiation Oncology, vol. 10, No. 3 Jul. 2000: pp. 175-190. [cited by examiner]
American Cancer Society, https://www.cancer.org/cancer/diagnosis-staging/signs-and-symptoms-of-cancer.html, 4 pages, accessed Sep. 5, 2024. [cited by examiner]
Andersen MH et al., “Phosphorylated Peptides can be Transported by TAP Molecules, Presented by Class I MHC Molecules, and Recognized by Phosphopeptide-Specific CTL,” J Immunol, 163: 3812-3818, 1999. [cited by applicant]
Greenspan et al., “Defining epitopes: It's not as easy as it seems,” Nature Biotechnology, 1999, 7: 936-937. [cited by applicant]
Guo et al., “Macrophage-Derived Chemokine Gene Transfer Results in Tumor Regression in Murine Lung Carcinoma Model through Efficient Induction of Antitumor Immunity,” Gene Therapy, vol. 9, No. 12, 2002, 793-803. [cited by applicant]
Kovjazin et al., “The use of signal peptide domains as vaccine candidates,” Human Vaccines & Immunotherapeutics, Sep. 2014, 10:9, 2733-2740. [cited by applicant]
Qin et al., “CCL22 Recruits CD4-positive CD25-positive Regulatory T Cells into Malignant Pleural Effusion,” Clin Cancer Res. 15(7), 2231-2237, 2009. [cited by applicant]
Sabado et al., “Dendritic cell-based immunotherapy,” Cell Research (2017) 27:74-95. [cited by applicant]
Calis, Jorg J. A. et al., “Properties of MHC Class I Presented Peptides That Enhance Immunogenicity”, PLOS Computational Biology 9(10):e1003266, 1-13 (2013). [cited by applicant]
Chang M S. et al., “Molecular cloning and functional characterization of a novel CC chemokine, stimulated T cell chemotactic protein (STCP-1) that specifically acts on activated T lymphocytes”, Journal of Biological Che… [cited by applicant]
Comber, J. D. and Philip, R., “MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines,” Ther Adv Vaccines, 2(3):77-89 (2014). [cited by applicant]
Purcell, Anthony W. et al., “More Than One Reason to Rethink the Use of Peptides in Vaccine Design”, Nature Reviews | Drug Discovery 6(5):404-414 (2007). [cited by applicant]